nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—HIF1A—thyroid cancer	0.457	1	CbGaD
Carvedilol—VEGFA—Vandetanib—thyroid cancer	0.279	0.794	CbGbCtD
Carvedilol—XDH—Doxorubicin—thyroid cancer	0.0307	0.0872	CbGbCtD
Carvedilol—CYP1A2—Sorafenib—thyroid cancer	0.00659	0.0187	CbGbCtD
Carvedilol—CYP2C9—Sorafenib—thyroid cancer	0.00593	0.0169	CbGbCtD
Carvedilol—ABCB1—Sorafenib—thyroid cancer	0.00576	0.0164	CbGbCtD
Carvedilol—CYP3A4—Vandetanib—thyroid cancer	0.00572	0.0163	CbGbCtD
Carvedilol—CYP2D6—Sorafenib—thyroid cancer	0.00543	0.0154	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—thyroid cancer	0.00349	0.00994	CbGbCtD
Carvedilol—CYP3A4—Sorafenib—thyroid cancer	0.00345	0.00981	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—thyroid cancer	0.00329	0.00936	CbGbCtD
Carvedilol—VCAM1—neck—thyroid cancer	0.0021	0.0484	CbGeAlD
Carvedilol—CYP3A4—Doxorubicin—thyroid cancer	0.00209	0.00595	CbGbCtD
Carvedilol—HIF1A—neck—thyroid cancer	0.00202	0.0465	CbGeAlD
Carvedilol—GJA1—neck—thyroid cancer	0.00196	0.0451	CbGeAlD
Carvedilol—SELE—saliva-secreting gland—thyroid cancer	0.00178	0.041	CbGeAlD
Carvedilol—NDUFC2—neck—thyroid cancer	0.00171	0.0393	CbGeAlD
Carvedilol—VCAM1—saliva-secreting gland—thyroid cancer	0.00164	0.0377	CbGeAlD
Carvedilol—HIF1A—saliva-secreting gland—thyroid cancer	0.00158	0.0363	CbGeAlD
Carvedilol—GJA1—saliva-secreting gland—thyroid cancer	0.00153	0.0352	CbGeAlD
Carvedilol—NPPB—head—thyroid cancer	0.00143	0.0329	CbGeAlD
Carvedilol—SELE—trachea—thyroid cancer	0.00137	0.0316	CbGeAlD
Carvedilol—NDUFC2—saliva-secreting gland—thyroid cancer	0.00133	0.0306	CbGeAlD
Carvedilol—VCAM1—trachea—thyroid cancer	0.00126	0.0291	CbGeAlD
Carvedilol—HIF1A—trachea—thyroid cancer	0.00122	0.028	CbGeAlD
Carvedilol—GJA1—trachea—thyroid cancer	0.00118	0.0272	CbGeAlD
Carvedilol—SELE—thyroid gland—thyroid cancer	0.00109	0.025	CbGeAlD
Carvedilol—NDUFC2—trachea—thyroid cancer	0.00103	0.0236	CbGeAlD
Carvedilol—VCAM1—thyroid gland—thyroid cancer	0.001	0.023	CbGeAlD
Carvedilol—SELE—head—thyroid cancer	0.000964	0.0222	CbGeAlD
Carvedilol—HIF1A—thyroid gland—thyroid cancer	0.000962	0.0221	CbGeAlD
Carvedilol—GJA1—thyroid gland—thyroid cancer	0.000933	0.0215	CbGeAlD
Carvedilol—VEGFA—trachea—thyroid cancer	0.000932	0.0214	CbGeAlD
Carvedilol—VCAM1—head—thyroid cancer	0.000887	0.0204	CbGeAlD
Carvedilol—HIF1A—head—thyroid cancer	0.000854	0.0196	CbGeAlD
Carvedilol—GJA1—head—thyroid cancer	0.000828	0.0191	CbGeAlD
Carvedilol—NDUFC2—thyroid gland—thyroid cancer	0.000812	0.0187	CbGeAlD
Carvedilol—VEGFA—thyroid gland—thyroid cancer	0.000737	0.017	CbGeAlD
Carvedilol—NDUFC2—head—thyroid cancer	0.000721	0.0166	CbGeAlD
Carvedilol—SELE—lymph node—thyroid cancer	0.000675	0.0155	CbGeAlD
Carvedilol—VCAM1—lymph node—thyroid cancer	0.000621	0.0143	CbGeAlD
Carvedilol—HIF1A—lymph node—thyroid cancer	0.000598	0.0138	CbGeAlD
Carvedilol—GJA1—lymph node—thyroid cancer	0.00058	0.0133	CbGeAlD
Carvedilol—NDUFC2—lymph node—thyroid cancer	0.000505	0.0116	CbGeAlD
Carvedilol—VEGFA—lymph node—thyroid cancer	0.000458	0.0105	CbGeAlD
Carvedilol—ADRA1B—head—thyroid cancer	0.000437	0.0101	CbGeAlD
Carvedilol—ADRA1D—head—thyroid cancer	0.000427	0.00983	CbGeAlD
Carvedilol—ADRA2C—trachea—thyroid cancer	0.000333	0.00767	CbGeAlD
Carvedilol—ADRB1—head—thyroid cancer	0.00031	0.00714	CbGeAlD
Carvedilol—CYP1A1—trachea—thyroid cancer	0.000285	0.00656	CbGeAlD
Carvedilol—ADRA2A—trachea—thyroid cancer	0.000266	0.00612	CbGeAlD
Carvedilol—PTGS1—trachea—thyroid cancer	0.00025	0.00577	CbGeAlD
Carvedilol—ADRA1A—head—thyroid cancer	0.000245	0.00565	CbGeAlD
Carvedilol—KCNH2—head—thyroid cancer	0.000237	0.00545	CbGeAlD
Carvedilol—ADRA2C—head—thyroid cancer	0.000234	0.00538	CbGeAlD
Carvedilol—CYP1A2—thyroid gland—thyroid cancer	0.000229	0.00526	CbGeAlD
Carvedilol—CYP1A1—thyroid gland—thyroid cancer	0.000226	0.00519	CbGeAlD
Carvedilol—ADRA2A—thyroid gland—thyroid cancer	0.00021	0.00484	CbGeAlD
Carvedilol—CYP2E1—thyroid gland—thyroid cancer	0.000206	0.00474	CbGeAlD
Carvedilol—CYP1A1—head—thyroid cancer	0.0002	0.00461	CbGeAlD
Carvedilol—PTGS1—thyroid gland—thyroid cancer	0.000198	0.00456	CbGeAlD
Carvedilol—ADRA2A—head—thyroid cancer	0.000187	0.00429	CbGeAlD
Carvedilol—CYP2E1—head—thyroid cancer	0.000182	0.0042	CbGeAlD
Carvedilol—PTGS1—head—thyroid cancer	0.000176	0.00405	CbGeAlD
Carvedilol—KCNH2—lymph node—thyroid cancer	0.000166	0.00382	CbGeAlD
Carvedilol—ADRA2C—lymph node—thyroid cancer	0.000164	0.00377	CbGeAlD
Carvedilol—ABCB1—trachea—thyroid cancer	0.000148	0.00341	CbGeAlD
Carvedilol—CYP2D6—head—thyroid cancer	0.000144	0.00333	CbGeAlD
Carvedilol—CYP1A1—lymph node—thyroid cancer	0.00014	0.00323	CbGeAlD
Carvedilol—Mental disability—Doxorubicin—thyroid cancer	0.000133	0.0017	CcSEcCtD
Carvedilol—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000131	0.00167	CcSEcCtD
Carvedilol—ADRA2A—lymph node—thyroid cancer	0.000131	0.00301	CbGeAlD
Carvedilol—Renal failure acute—Epirubicin—thyroid cancer	0.00013	0.00167	CcSEcCtD
Carvedilol—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000128	0.00164	CcSEcCtD
Carvedilol—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000128	0.00164	CcSEcCtD
Carvedilol—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000128	0.00163	CcSEcCtD
Carvedilol—Urticaria—Sorafenib—thyroid cancer	0.000127	0.00163	CcSEcCtD
Carvedilol—Abdominal pain—Sorafenib—thyroid cancer	0.000127	0.00162	CcSEcCtD
Carvedilol—Body temperature increased—Sorafenib—thyroid cancer	0.000127	0.00162	CcSEcCtD
Carvedilol—Renal impairment—Epirubicin—thyroid cancer	0.000127	0.00162	CcSEcCtD
Carvedilol—Purpura—Epirubicin—thyroid cancer	0.000125	0.0016	CcSEcCtD
Carvedilol—Vascular purpura—Doxorubicin—thyroid cancer	0.000125	0.00159	CcSEcCtD
Carvedilol—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000124	0.00159	CcSEcCtD
Carvedilol—Hypoglycaemia—Epirubicin—thyroid cancer	0.000123	0.00158	CcSEcCtD
Carvedilol—Cardiac failure—Epirubicin—thyroid cancer	0.000123	0.00158	CcSEcCtD
Carvedilol—PTGS1—lymph node—thyroid cancer	0.000123	0.00283	CbGeAlD
Carvedilol—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000123	0.00157	CcSEcCtD
Carvedilol—Hyponatraemia—Epirubicin—thyroid cancer	0.000121	0.00154	CcSEcCtD
Carvedilol—Renal failure acute—Doxorubicin—thyroid cancer	0.000121	0.00154	CcSEcCtD
Carvedilol—Pain in extremity—Epirubicin—thyroid cancer	0.00012	0.00154	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00012	0.00154	CcSEcCtD
Carvedilol—Affect lability—Epirubicin—thyroid cancer	0.000119	0.00151	CcSEcCtD
Carvedilol—Migraine—Epirubicin—thyroid cancer	0.000119	0.00151	CcSEcCtD
Carvedilol—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000118	0.00151	CcSEcCtD
Carvedilol—Hypersensitivity—Sorafenib—thyroid cancer	0.000118	0.00151	CcSEcCtD
Carvedilol—ABCB1—thyroid gland—thyroid cancer	0.000117	0.0027	CbGeAlD
Carvedilol—Renal impairment—Doxorubicin—thyroid cancer	0.000117	0.0015	CcSEcCtD
Carvedilol—Purpura—Doxorubicin—thyroid cancer	0.000116	0.00148	CcSEcCtD
Carvedilol—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000115	0.00147	CcSEcCtD
Carvedilol—Asthenia—Sorafenib—thyroid cancer	0.000115	0.00147	CcSEcCtD
Carvedilol—Cardiac arrest—Epirubicin—thyroid cancer	0.000114	0.00146	CcSEcCtD
Carvedilol—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000114	0.00146	CcSEcCtD
Carvedilol—Cardiac failure—Doxorubicin—thyroid cancer	0.000114	0.00146	CcSEcCtD
Carvedilol—Mood swings—Epirubicin—thyroid cancer	0.000114	0.00146	CcSEcCtD
Carvedilol—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000114	0.00145	CcSEcCtD
Carvedilol—Pruritus—Sorafenib—thyroid cancer	0.000113	0.00145	CcSEcCtD
Carvedilol—Blood creatinine increased—Epirubicin—thyroid cancer	0.000113	0.00144	CcSEcCtD
Carvedilol—Dehydration—Epirubicin—thyroid cancer	0.000112	0.00143	CcSEcCtD
Carvedilol—Hyponatraemia—Doxorubicin—thyroid cancer	0.000112	0.00143	CcSEcCtD
Carvedilol—Pain in extremity—Doxorubicin—thyroid cancer	0.000111	0.00142	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000111	0.00142	CcSEcCtD
Carvedilol—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00011	0.00141	CcSEcCtD
Carvedilol—Migraine—Doxorubicin—thyroid cancer	0.00011	0.0014	CcSEcCtD
Carvedilol—Affect lability—Doxorubicin—thyroid cancer	0.00011	0.0014	CcSEcCtD
Carvedilol—Hypokalaemia—Epirubicin—thyroid cancer	0.00011	0.0014	CcSEcCtD
Carvedilol—Diarrhoea—Sorafenib—thyroid cancer	0.00011	0.0014	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000108	0.00139	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000108	0.00139	CcSEcCtD
Carvedilol—Nasopharyngitis—Epirubicin—thyroid cancer	0.000108	0.00138	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000106	0.00136	CcSEcCtD
Carvedilol—Cardiac arrest—Doxorubicin—thyroid cancer	0.000106	0.00135	CcSEcCtD
Carvedilol—Dizziness—Sorafenib—thyroid cancer	0.000106	0.00135	CcSEcCtD
Carvedilol—Mood swings—Doxorubicin—thyroid cancer	0.000106	0.00135	CcSEcCtD
Carvedilol—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000104	0.00133	CcSEcCtD
Carvedilol—Influenza—Epirubicin—thyroid cancer	0.000104	0.00133	CcSEcCtD
Carvedilol—ABCB1—head—thyroid cancer	0.000104	0.00239	CbGeAlD
Carvedilol—Dehydration—Doxorubicin—thyroid cancer	0.000104	0.00132	CcSEcCtD
Carvedilol—Vomiting—Sorafenib—thyroid cancer	0.000102	0.0013	CcSEcCtD
Carvedilol—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000102	0.0013	CcSEcCtD
Carvedilol—Hypokalaemia—Doxorubicin—thyroid cancer	0.000101	0.0013	CcSEcCtD
Carvedilol—Angina pectoris—Epirubicin—thyroid cancer	0.000101	0.0013	CcSEcCtD
Carvedilol—Rash—Sorafenib—thyroid cancer	0.000101	0.00129	CcSEcCtD
Carvedilol—Dermatitis—Sorafenib—thyroid cancer	0.000101	0.00129	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.0001	0.00128	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.0001	0.00128	CcSEcCtD
Carvedilol—Headache—Sorafenib—thyroid cancer	0.0001	0.00128	CcSEcCtD
Carvedilol—Bronchitis—Epirubicin—thyroid cancer	0.0001	0.00128	CcSEcCtD
Carvedilol—Nasopharyngitis—Doxorubicin—thyroid cancer	9.96e-05	0.00127	CcSEcCtD
Carvedilol—Pancytopenia—Epirubicin—thyroid cancer	9.88e-05	0.00126	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	9.83e-05	0.00126	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Epirubicin—thyroid cancer	9.67e-05	0.00124	CcSEcCtD
Carvedilol—Influenza—Doxorubicin—thyroid cancer	9.63e-05	0.00123	CcSEcCtD
Carvedilol—Pollakiuria—Epirubicin—thyroid cancer	9.61e-05	0.00123	CcSEcCtD
Carvedilol—Nausea—Sorafenib—thyroid cancer	9.51e-05	0.00122	CcSEcCtD
Carvedilol—Photosensitivity reaction—Epirubicin—thyroid cancer	9.5e-05	0.00121	CcSEcCtD
Carvedilol—Weight increased—Epirubicin—thyroid cancer	9.47e-05	0.00121	CcSEcCtD
Carvedilol—Weight decreased—Epirubicin—thyroid cancer	9.42e-05	0.0012	CcSEcCtD
Carvedilol—Hyperglycaemia—Epirubicin—thyroid cancer	9.39e-05	0.0012	CcSEcCtD
Carvedilol—Angina pectoris—Doxorubicin—thyroid cancer	9.38e-05	0.0012	CcSEcCtD
Carvedilol—Pneumonia—Epirubicin—thyroid cancer	9.33e-05	0.00119	CcSEcCtD
Carvedilol—Bronchitis—Doxorubicin—thyroid cancer	9.26e-05	0.00118	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	9.2e-05	0.00118	CcSEcCtD
Carvedilol—Pancytopenia—Doxorubicin—thyroid cancer	9.14e-05	0.00117	CcSEcCtD
Carvedilol—Renal failure—Epirubicin—thyroid cancer	9.12e-05	0.00117	CcSEcCtD
Carvedilol—Urinary tract infection—Epirubicin—thyroid cancer	9.02e-05	0.00115	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Doxorubicin—thyroid cancer	8.95e-05	0.00114	CcSEcCtD
Carvedilol—Pollakiuria—Doxorubicin—thyroid cancer	8.9e-05	0.00114	CcSEcCtD
Carvedilol—Haematuria—Epirubicin—thyroid cancer	8.85e-05	0.00113	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—thyroid cancer	8.79e-05	0.00112	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—thyroid cancer	8.76e-05	0.00112	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—thyroid cancer	8.71e-05	0.00111	CcSEcCtD
Carvedilol—Sinusitis—Epirubicin—thyroid cancer	8.71e-05	0.00111	CcSEcCtD
Carvedilol—Hyperglycaemia—Doxorubicin—thyroid cancer	8.69e-05	0.00111	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—thyroid cancer	8.64e-05	0.0011	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	8.51e-05	0.00109	CcSEcCtD
Carvedilol—Bradycardia—Epirubicin—thyroid cancer	8.48e-05	0.00108	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—thyroid cancer	8.44e-05	0.00108	CcSEcCtD
Carvedilol—Haemoglobin—Epirubicin—thyroid cancer	8.37e-05	0.00107	CcSEcCtD
Carvedilol—Rhinitis—Epirubicin—thyroid cancer	8.35e-05	0.00107	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—thyroid cancer	8.35e-05	0.00107	CcSEcCtD
Carvedilol—Haemorrhage—Epirubicin—thyroid cancer	8.33e-05	0.00106	CcSEcCtD
Carvedilol—Hypoaesthesia—Epirubicin—thyroid cancer	8.29e-05	0.00106	CcSEcCtD
Carvedilol—Pharyngitis—Epirubicin—thyroid cancer	8.27e-05	0.00106	CcSEcCtD
Carvedilol—Urinary tract disorder—Epirubicin—thyroid cancer	8.23e-05	0.00105	CcSEcCtD
Carvedilol—Oedema peripheral—Epirubicin—thyroid cancer	8.21e-05	0.00105	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—thyroid cancer	8.19e-05	0.00105	CcSEcCtD
Carvedilol—Urethral disorder—Epirubicin—thyroid cancer	8.17e-05	0.00104	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—thyroid cancer	8.06e-05	0.00103	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—thyroid cancer	8.03e-05	0.00103	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—thyroid cancer	7.88e-05	0.00101	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—thyroid cancer	7.85e-05	0.001	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—thyroid cancer	7.77e-05	0.000992	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—thyroid cancer	7.75e-05	0.00099	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—thyroid cancer	7.73e-05	0.000987	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—thyroid cancer	7.71e-05	0.000985	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—thyroid cancer	7.67e-05	0.00098	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—thyroid cancer	7.65e-05	0.000977	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—thyroid cancer	7.61e-05	0.000973	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—thyroid cancer	7.59e-05	0.00097	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—thyroid cancer	7.56e-05	0.000966	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—thyroid cancer	7.56e-05	0.000965	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—thyroid cancer	7.52e-05	0.000961	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—thyroid cancer	7.51e-05	0.000959	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—thyroid cancer	7.43e-05	0.000949	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—thyroid cancer	7.36e-05	0.00094	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—thyroid cancer	7.29e-05	0.000931	CcSEcCtD
Carvedilol—ABCB1—lymph node—thyroid cancer	7.28e-05	0.00168	CbGeAlD
Carvedilol—Malnutrition—Epirubicin—thyroid cancer	7.25e-05	0.000926	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—thyroid cancer	7.19e-05	0.000918	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—thyroid cancer	7.15e-05	0.000913	CcSEcCtD
Carvedilol—Tension—Epirubicin—thyroid cancer	7.12e-05	0.000909	CcSEcCtD
Carvedilol—Nervousness—Epirubicin—thyroid cancer	7.04e-05	0.0009	CcSEcCtD
Carvedilol—Back pain—Epirubicin—thyroid cancer	7.01e-05	0.000896	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—thyroid cancer	6.99e-05	0.000893	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—thyroid cancer	6.97e-05	0.000891	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—thyroid cancer	6.96e-05	0.00089	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—thyroid cancer	6.95e-05	0.000888	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—thyroid cancer	6.83e-05	0.000873	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—thyroid cancer	6.81e-05	0.00087	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—thyroid cancer	6.73e-05	0.00086	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—thyroid cancer	6.71e-05	0.000857	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—thyroid cancer	6.7e-05	0.000856	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—thyroid cancer	6.61e-05	0.000845	CcSEcCtD
Carvedilol—Tension—Doxorubicin—thyroid cancer	6.58e-05	0.000841	CcSEcCtD
Carvedilol—Malaise—Epirubicin—thyroid cancer	6.54e-05	0.000836	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—thyroid cancer	6.52e-05	0.000833	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—thyroid cancer	6.52e-05	0.000832	CcSEcCtD
Carvedilol—Syncope—Epirubicin—thyroid cancer	6.5e-05	0.000831	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—thyroid cancer	6.49e-05	0.000829	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—thyroid cancer	6.49e-05	0.000829	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—thyroid cancer	6.45e-05	0.000824	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—thyroid cancer	6.41e-05	0.000819	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—thyroid cancer	6.37e-05	0.000814	CcSEcCtD
Carvedilol—Cough—Epirubicin—thyroid cancer	6.33e-05	0.000808	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—thyroid cancer	6.32e-05	0.000808	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—thyroid cancer	6.28e-05	0.000803	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—thyroid cancer	6.26e-05	0.0008	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—thyroid cancer	6.23e-05	0.000795	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—thyroid cancer	6.2e-05	0.000792	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—thyroid cancer	6.17e-05	0.000789	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—thyroid cancer	6.17e-05	0.000789	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—thyroid cancer	6.17e-05	0.000789	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	6.13e-05	0.000783	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—thyroid cancer	6.1e-05	0.000779	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—thyroid cancer	6.05e-05	0.000773	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—thyroid cancer	6.04e-05	0.000771	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—thyroid cancer	6.03e-05	0.00077	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—thyroid cancer	6.02e-05	0.000769	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—thyroid cancer	6.01e-05	0.000767	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—thyroid cancer	5.97e-05	0.000762	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—thyroid cancer	5.93e-05	0.000758	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—thyroid cancer	5.92e-05	0.000756	CcSEcCtD
Carvedilol—Oedema—Epirubicin—thyroid cancer	5.92e-05	0.000756	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—thyroid cancer	5.9e-05	0.000753	CcSEcCtD
Carvedilol—Infection—Epirubicin—thyroid cancer	5.88e-05	0.000751	CcSEcCtD
Carvedilol—Cough—Doxorubicin—thyroid cancer	5.86e-05	0.000748	CcSEcCtD
Carvedilol—Shock—Epirubicin—thyroid cancer	5.82e-05	0.000744	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—thyroid cancer	5.81e-05	0.000743	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—thyroid cancer	5.79e-05	0.00074	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—thyroid cancer	5.79e-05	0.00074	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—thyroid cancer	5.78e-05	0.000738	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—thyroid cancer	5.75e-05	0.000734	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—thyroid cancer	5.72e-05	0.000731	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—thyroid cancer	5.71e-05	0.00073	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—thyroid cancer	5.71e-05	0.00073	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—thyroid cancer	5.71e-05	0.00073	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	5.67e-05	0.000725	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—thyroid cancer	5.64e-05	0.000721	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—thyroid cancer	5.64e-05	0.000721	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—thyroid cancer	5.59e-05	0.000714	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—thyroid cancer	5.53e-05	0.000707	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—thyroid cancer	5.52e-05	0.000705	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—thyroid cancer	5.48e-05	0.0007	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—thyroid cancer	5.48e-05	0.0007	CcSEcCtD
Carvedilol—Infection—Doxorubicin—thyroid cancer	5.44e-05	0.000695	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—thyroid cancer	5.39e-05	0.000689	CcSEcCtD
Carvedilol—Shock—Doxorubicin—thyroid cancer	5.39e-05	0.000688	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—thyroid cancer	5.36e-05	0.000685	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—thyroid cancer	5.35e-05	0.000684	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—thyroid cancer	5.34e-05	0.000683	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—thyroid cancer	5.32e-05	0.00068	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—thyroid cancer	5.31e-05	0.000679	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—thyroid cancer	5.29e-05	0.000676	CcSEcCtD
Carvedilol—Dyspnoea—Epirubicin—thyroid cancer	5.28e-05	0.000674	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—thyroid cancer	5.26e-05	0.000672	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—thyroid cancer	5.22e-05	0.000667	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—thyroid cancer	5.21e-05	0.000666	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—thyroid cancer	5.14e-05	0.000657	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—thyroid cancer	5.12e-05	0.000654	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—thyroid cancer	5.11e-05	0.000653	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—thyroid cancer	5.1e-05	0.000652	CcSEcCtD
Carvedilol—Pain—Epirubicin—thyroid cancer	5.06e-05	0.000647	CcSEcCtD
Carvedilol—Constipation—Epirubicin—thyroid cancer	5.06e-05	0.000647	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	4.99e-05	0.000637	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—thyroid cancer	4.95e-05	0.000633	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—thyroid cancer	4.92e-05	0.000628	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—thyroid cancer	4.88e-05	0.000624	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—thyroid cancer	4.88e-05	0.000623	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—thyroid cancer	4.87e-05	0.000622	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—thyroid cancer	4.84e-05	0.000618	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—thyroid cancer	4.82e-05	0.000616	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—thyroid cancer	4.76e-05	0.000608	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—thyroid cancer	4.73e-05	0.000604	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—thyroid cancer	4.72e-05	0.000603	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—thyroid cancer	4.7e-05	0.000601	CcSEcCtD
Carvedilol—Pain—Doxorubicin—thyroid cancer	4.68e-05	0.000598	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—thyroid cancer	4.68e-05	0.000598	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—thyroid cancer	4.68e-05	0.000598	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—thyroid cancer	4.68e-05	0.000598	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—thyroid cancer	4.51e-05	0.000577	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—thyroid cancer	4.48e-05	0.000572	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—thyroid cancer	4.36e-05	0.000557	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—thyroid cancer	4.35e-05	0.000556	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—thyroid cancer	4.33e-05	0.000553	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—thyroid cancer	4.33e-05	0.000553	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—thyroid cancer	4.25e-05	0.000543	CcSEcCtD
Carvedilol—Pruritus—Epirubicin—thyroid cancer	4.19e-05	0.000535	CcSEcCtD
Carvedilol—Diarrhoea—Epirubicin—thyroid cancer	4.05e-05	0.000517	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—thyroid cancer	4.03e-05	0.000515	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—thyroid cancer	3.93e-05	0.000502	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—thyroid cancer	3.91e-05	0.0005	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—thyroid cancer	3.87e-05	0.000495	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—thyroid cancer	3.76e-05	0.000481	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—thyroid cancer	3.75e-05	0.000479	CcSEcCtD
Carvedilol—Rash—Epirubicin—thyroid cancer	3.73e-05	0.000477	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—thyroid cancer	3.73e-05	0.000476	CcSEcCtD
Carvedilol—Headache—Epirubicin—thyroid cancer	3.71e-05	0.000474	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—thyroid cancer	3.62e-05	0.000463	CcSEcCtD
Carvedilol—Nausea—Epirubicin—thyroid cancer	3.52e-05	0.000449	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—thyroid cancer	3.48e-05	0.000445	CcSEcCtD
Carvedilol—Rash—Doxorubicin—thyroid cancer	3.45e-05	0.000441	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—thyroid cancer	3.45e-05	0.000441	CcSEcCtD
Carvedilol—Headache—Doxorubicin—thyroid cancer	3.43e-05	0.000438	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—thyroid cancer	3.25e-05	0.000416	CcSEcCtD
Carvedilol—ADRA2C—Hemostasis—NRAS—thyroid cancer	7.05e-06	0.000101	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CDK1—thyroid cancer	7.05e-06	0.000101	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—BRAF—thyroid cancer	6.93e-06	9.93e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—BRAF—thyroid cancer	6.91e-06	9.91e-05	CbGpPWpGaD
Carvedilol—XDH—Metabolism—PTEN—thyroid cancer	6.83e-06	9.8e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTCH1—thyroid cancer	6.79e-06	9.74e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SST—thyroid cancer	6.69e-06	9.59e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDK1—thyroid cancer	6.67e-06	9.56e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—TPR—thyroid cancer	6.61e-06	9.47e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	6.61e-06	9.47e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—SLC5A5—thyroid cancer	6.57e-06	9.42e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDK1—thyroid cancer	6.56e-06	9.41e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—AKT1—thyroid cancer	6.5e-06	9.32e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PRKAR1A—thyroid cancer	6.5e-06	9.32e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—KRAS—thyroid cancer	6.5e-06	9.32e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CALCA—thyroid cancer	6.44e-06	9.23e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRG1—thyroid cancer	6.35e-06	9.1e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—KRAS—thyroid cancer	6.34e-06	9.09e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—TPR—thyroid cancer	6.23e-06	8.93e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SST—thyroid cancer	6.21e-06	8.91e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—SLC5A5—thyroid cancer	6.19e-06	8.88e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—TPR—thyroid cancer	6.17e-06	8.85e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	6.13e-06	8.78e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	6.07e-06	8.71e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—KRAS—thyroid cancer	6.07e-06	8.7e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—RXRA—thyroid cancer	6.01e-06	8.62e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CALCA—thyroid cancer	5.98e-06	8.58e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDK1—thyroid cancer	5.83e-06	8.35e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.8e-06	8.32e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRG1—thyroid cancer	5.78e-06	8.29e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—thyroid cancer	5.78e-06	8.28e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NRAS—thyroid cancer	5.73e-06	8.21e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRG1—thyroid cancer	5.73e-06	8.21e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TERT—thyroid cancer	5.7e-06	8.17e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRG1—thyroid cancer	5.66e-06	8.11e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.58e-06	8e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—HRAS—thyroid cancer	5.52e-06	7.92e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—RXRA—thyroid cancer	5.52e-06	7.91e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.51e-06	7.89e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HIF1A—thyroid cancer	5.45e-06	7.81e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDK1—thyroid cancer	5.41e-06	7.76e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—thyroid cancer	5.4e-06	7.74e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—HRAS—thyroid cancer	5.39e-06	7.73e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRG1—thyroid cancer	5.35e-06	7.67e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TPR—thyroid cancer	5.28e-06	7.56e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRG1—thyroid cancer	5.27e-06	7.55e-05	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—AKT1—thyroid cancer	5.24e-06	7.51e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—RXRA—thyroid cancer	5.2e-06	7.46e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TERT—thyroid cancer	5.19e-06	7.44e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	5.19e-06	7.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—HRAS—thyroid cancer	5.16e-06	7.4e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TERT—thyroid cancer	5.14e-06	7.37e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TERT—thyroid cancer	5.08e-06	7.28e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.06e-06	7.26e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CCND1—thyroid cancer	5.05e-06	7.25e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CCND1—thyroid cancer	5.04e-06	7.23e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HIF1A—thyroid cancer	4.96e-06	7.12e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—SLC5A5—thyroid cancer	4.95e-06	7.09e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—KRAS—thyroid cancer	4.93e-06	7.07e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HIF1A—thyroid cancer	4.92e-06	7.05e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—PTEN—thyroid cancer	4.88e-06	6.99e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—AKT1—thyroid cancer	4.88e-06	6.99e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—PTEN—thyroid cancer	4.87e-06	6.98e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HIF1A—thyroid cancer	4.86e-06	6.96e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TERT—thyroid cancer	4.8e-06	6.89e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—NRAS—thyroid cancer	4.8e-06	6.88e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—AKT1—thyroid cancer	4.76e-06	6.82e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TERT—thyroid cancer	4.73e-06	6.78e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.7e-06	6.74e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRG1—thyroid cancer	4.68e-06	6.71e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PPARG—thyroid cancer	4.67e-06	6.7e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PPARG—thyroid cancer	4.66e-06	6.69e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—SLC5A5—thyroid cancer	4.66e-06	6.68e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—SLC5A5—thyroid cancer	4.62e-06	6.63e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HIF1A—thyroid cancer	4.59e-06	6.59e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—AKT1—thyroid cancer	4.56e-06	6.53e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HIF1A—thyroid cancer	4.52e-06	6.48e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—BRAF—thyroid cancer	4.51e-06	6.47e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—thyroid cancer	4.38e-06	6.28e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—NRAS—thyroid cancer	4.37e-06	6.27e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NRAS—thyroid cancer	4.35e-06	6.24e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRG1—thyroid cancer	4.35e-06	6.23e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NRAS—thyroid cancer	4.34e-06	6.23e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—NRAS—thyroid cancer	4.33e-06	6.21e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.33e-06	6.21e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—NRAS—thyroid cancer	4.28e-06	6.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TERT—thyroid cancer	4.2e-06	6.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—HRAS—thyroid cancer	4.19e-06	6.01e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—RXRA—thyroid cancer	4.16e-06	5.96e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—KRAS—thyroid cancer	4.13e-06	5.92e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—BRAF—thyroid cancer	4.11e-06	5.89e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—BRAF—thyroid cancer	4.07e-06	5.84e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TPR—thyroid cancer	4.07e-06	5.84e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—NRAS—thyroid cancer	4.05e-06	5.8e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—BRAF—thyroid cancer	4.02e-06	5.77e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	4.02e-06	5.76e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	4.01e-06	5.74e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—NRAS—thyroid cancer	3.98e-06	5.71e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—SLC5A5—thyroid cancer	3.95e-06	5.66e-05	CbGpPWpGaD
Carvedilol—XDH—Metabolism—AKT1—thyroid cancer	3.94e-06	5.65e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—RXRA—thyroid cancer	3.92e-06	5.61e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TERT—thyroid cancer	3.9e-06	5.59e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—RXRA—thyroid cancer	3.88e-06	5.57e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—BRAF—thyroid cancer	3.81e-06	5.45e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PPARG—thyroid cancer	3.8e-06	5.44e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.78e-06	5.41e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—KRAS—thyroid cancer	3.76e-06	5.4e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KRAS—thyroid cancer	3.75e-06	5.37e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—BRAF—thyroid cancer	3.74e-06	5.37e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KRAS—thyroid cancer	3.74e-06	5.36e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	3.73e-06	5.35e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—KRAS—thyroid cancer	3.73e-06	5.35e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—AKT1—thyroid cancer	3.7e-06	5.31e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.7e-06	5.31e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—KRAS—thyroid cancer	3.68e-06	5.28e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—thyroid cancer	3.68e-06	5.27e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—thyroid cancer	3.67e-06	5.26e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	3.54e-06	5.07e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HRAS—thyroid cancer	3.51e-06	5.03e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PPARG—thyroid cancer	3.49e-06	5e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—KRAS—thyroid cancer	3.48e-06	4.99e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—KRAS—thyroid cancer	3.43e-06	4.92e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—AKT1—thyroid cancer	3.41e-06	4.89e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—thyroid cancer	3.33e-06	4.77e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	3.33e-06	4.77e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—thyroid cancer	3.32e-06	4.76e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—RXRA—thyroid cancer	3.32e-06	4.76e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCND1—thyroid cancer	3.29e-06	4.72e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	3.29e-06	4.71e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PPARG—thyroid cancer	3.29e-06	4.71e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.23e-06	4.63e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTEN—thyroid cancer	3.21e-06	4.6e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HRAS—thyroid cancer	3.2e-06	4.59e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTEN—thyroid cancer	3.2e-06	4.59e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—thyroid cancer	3.18e-06	4.57e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTEN—thyroid cancer	3.18e-06	4.56e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—thyroid cancer	3.18e-06	4.56e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—thyroid cancer	3.17e-06	4.54e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—thyroid cancer	3.13e-06	4.49e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—AKT1—thyroid cancer	3.11e-06	4.46e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—AKT1—thyroid cancer	3.1e-06	4.45e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	3.09e-06	4.43e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—AKT1—thyroid cancer	3.08e-06	4.42e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SLC5A5—thyroid cancer	3.05e-06	4.37e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	3.05e-06	4.37e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AKT1—thyroid cancer	3.04e-06	4.36e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—thyroid cancer	3e-06	4.3e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—thyroid cancer	2.99e-06	4.28e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—thyroid cancer	2.97e-06	4.26e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—thyroid cancer	2.96e-06	4.25e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—thyroid cancer	2.93e-06	4.21e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—thyroid cancer	2.91e-06	4.18e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTEN—thyroid cancer	2.9e-06	4.15e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKT1—thyroid cancer	2.88e-06	4.13e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTEN—thyroid cancer	2.87e-06	4.11e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—thyroid cancer	2.84e-06	4.06e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKT1—thyroid cancer	2.83e-06	4.06e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTEN—thyroid cancer	2.83e-06	4.06e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	2.83e-06	4.06e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—thyroid cancer	2.83e-06	4.05e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—thyroid cancer	2.81e-06	4.03e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—thyroid cancer	2.81e-06	4.02e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—thyroid cancer	2.8e-06	4.01e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—thyroid cancer	2.78e-06	3.98e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—thyroid cancer	2.76e-06	3.96e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—thyroid cancer	2.74e-06	3.93e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—thyroid cancer	2.73e-06	3.92e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—thyroid cancer	2.68e-06	3.84e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—thyroid cancer	2.64e-06	3.78e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PPARG—thyroid cancer	2.62e-06	3.76e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—thyroid cancer	2.61e-06	3.75e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—thyroid cancer	2.6e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	2.59e-06	3.71e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—thyroid cancer	2.58e-06	3.71e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—thyroid cancer	2.58e-06	3.7e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—thyroid cancer	2.57e-06	3.69e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—RXRA—thyroid cancer	2.56e-06	3.67e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—thyroid cancer	2.56e-06	3.67e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—thyroid cancer	2.53e-06	3.62e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	2.52e-06	3.61e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARG—thyroid cancer	2.47e-06	3.55e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARG—thyroid cancer	2.45e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—thyroid cancer	2.44e-06	3.5e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	2.43e-06	3.48e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	2.41e-06	3.45e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—thyroid cancer	2.39e-06	3.43e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—thyroid cancer	2.39e-06	3.43e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—thyroid cancer	2.35e-06	3.37e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	2.34e-06	3.36e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	2.34e-06	3.35e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	2.29e-06	3.28e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	2.26e-06	3.23e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—thyroid cancer	2.25e-06	3.23e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—thyroid cancer	2.22e-06	3.19e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—thyroid cancer	2.2e-06	3.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	2.18e-06	3.12e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—thyroid cancer	2.18e-06	3.12e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—thyroid cancer	2.17e-06	3.11e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	2.12e-06	3.04e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARG—thyroid cancer	2.1e-06	3e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	2.09e-06	3e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—thyroid cancer	2.07e-06	2.97e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—thyroid cancer	2.06e-06	2.96e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—thyroid cancer	2.06e-06	2.95e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—thyroid cancer	2.03e-06	2.9e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—thyroid cancer	1.98e-06	2.83e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—thyroid cancer	1.96e-06	2.81e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.95e-06	2.79e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	1.94e-06	2.78e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—thyroid cancer	1.93e-06	2.77e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.93e-06	2.76e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—thyroid cancer	1.89e-06	2.71e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—thyroid cancer	1.87e-06	2.68e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—thyroid cancer	1.85e-06	2.65e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—thyroid cancer	1.85e-06	2.65e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—thyroid cancer	1.84e-06	2.64e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—thyroid cancer	1.83e-06	2.63e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—thyroid cancer	1.83e-06	2.62e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—thyroid cancer	1.8e-06	2.58e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—thyroid cancer	1.8e-06	2.58e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	1.8e-06	2.58e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—thyroid cancer	1.75e-06	2.51e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—thyroid cancer	1.72e-06	2.47e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—thyroid cancer	1.7e-06	2.43e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—thyroid cancer	1.68e-06	2.41e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	1.67e-06	2.4e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—thyroid cancer	1.67e-06	2.39e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—thyroid cancer	1.65e-06	2.37e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—thyroid cancer	1.65e-06	2.36e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—thyroid cancer	1.63e-06	2.34e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARG—thyroid cancer	1.62e-06	2.32e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—thyroid cancer	1.6e-06	2.29e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—thyroid cancer	1.54e-06	2.21e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	1.53e-06	2.19e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—thyroid cancer	1.52e-06	2.18e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—thyroid cancer	1.5e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—thyroid cancer	1.49e-06	2.13e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—thyroid cancer	1.44e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	1.42e-06	2.04e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—thyroid cancer	1.38e-06	1.98e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	1.35e-06	1.94e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—thyroid cancer	1.3e-06	1.86e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.27e-06	1.82e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	1.25e-06	1.8e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—thyroid cancer	1.11e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—thyroid cancer	1.04e-06	1.49e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—thyroid cancer	9.78e-07	1.4e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—thyroid cancer	9.69e-07	1.39e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—thyroid cancer	8.28e-07	1.19e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—thyroid cancer	6.39e-07	9.16e-06	CbGpPWpGaD
